Introduction
============

Antimicrobial peptides (AMPs) play a key role in many biological and physiological functions of living organisms and are an attractive starting point for the development of novel drugs.[@b1-ijn-10-6523],[@b2-ijn-10-6523] These peptides of the innate immune defense system are attracting widespread attention given the growing resistance to antibiotics.[@b3-ijn-10-6523] Among the most promising AMPs is the human β-defensins (hBDs) family that displays potent antimicrobial activity against gram-positive and gram-negative bacteria, fungi, viruses, and parasites.[@b4-ijn-10-6523] hBDs exert their effect by contacting and permeabilizing the cell membrane structure of microorganisms, and inhibiting DNA synthesis and deranging metabolism turnover.[@b5-ijn-10-6523] Consequently, defensins are an excellent springboard for the development of new molecules able to fight infectious diseases, even though they are inhibited in the presence of high concentrations of salt.[@b5-ijn-10-6523],[@b6-ijn-10-6523]

In this scenario, we previously designed a number of β-defensin analogs that have increased potency and/or reduced sensitivity to high ionic strength, and investigated their antibacterial, antiviral, and chemotactic activities, as well as their salt resistance.[@b7-ijn-10-6523],[@b8-ijn-10-6523] The results showed that the charged C-terminal domain (RRKK) of hBD3 and the internal domain of hBD1 (PIFTKIQGT) are crucial for defensin activity and that deletion of six residues at the N-terminus of hBD3 did not reduce the activity.[@b7-ijn-10-6523],[@b8-ijn-10-6523] Consequently, the internal region of hBD1 and the C-terminus of hBD3 are attractive domains in terms of engineering functional truncated defensin analogs. Notwithstanding these promising features, natural defensins have several properties that detract from their suitability as drug candidates, such as the fact that they are rapidly cleaved in human fluids by proteases.[@b9-ijn-10-6523] Another factor limiting the potential therapeutic use of defensins is the need for a single molecule with the correct pattern of disulfide bonds which is extremely complicated and expensive, while linear analogs with no disulfide bridges often occur in an ensemble of conformations that reduce their specificity for biological targets.[@b10-ijn-10-6523],[@b11-ijn-10-6523]

In an attempt to overcome the above drawbacks, structural restraints can be introduced to reduce the number of conformations, thus resulting in a higher affinity for the target and improved protease stability, bioavailability, and specificity. In particular, cyclization is frequently used by the pharmaceutical industry to reduce the flexibility of peptides and lock them into well-defined secondary structures.[@b1-ijn-10-6523],[@b3-ijn-10-6523] Moreover, cyclic peptides typically have a much higher stability and enhanced biopharmaceutical properties compared to their linear counterparts. Cyclization through disulfide bonds occurs naturally in AMPs such as hBDs that, despite the drawbacks mentioned above, display highly potent and broad antimicrobial activity.

We were inspired by the properties of θ-defensins, which are the only known ribosomally synthesized cyclic peptides in mammals and are hence protease-resistant and stable, and represent ideal scaffolds for peptide drug design. They present a cyclic cystine ladder motif, comprising a cyclic peptide backbone. The ease of synthesis, the stability, and the great diversity of cyclic peptides that can be produced make them suitable for a wide range of applications as drug scaffolds for bioactive peptides.

We have designed and synthesized an antimicrobial cyclic peptide (AMC) carrying the crucial active regions of hBD1 and hBD3. This new analog is not cytotoxic, it exerts effective antibacterial and antiviral activity, and is stable in blood. Given these features, this molecule may be considered a novel weapon in the fight against infectious diseases that has the potential of being encapsulated as a nanomedicine.

Materials and methods
=====================

General procedures
------------------

Fmoc-protected amino acids, coupling reagents, and Rink amide *p*-methylbenzhydrylamine resin were purchased from Calbiochem-Novabiochem (San Diego, CA, USA). All other chemicals were purchased from Sigma-Aldrich Co. (St Louis, MO, USA). Analytical and semi-prep reverse-phase high-performance liquid chromatography (HPLC) was performed on a Shimadzu LC8 pump setup using Phenomenex (Phenomenex, Aschaffenburg, Germany) C~18~ column (22×250 mm, 5 µm; or 4.6×250 mm, 5 µm). Serum stability was assessed by Liquid chromatography--Mass spectrometry (LC/MS) (Gilson, Middleton, WI, USA) interfaced with a Flexar SQ 300 mass spectrometer with electrospray ionization (PerkinElmer Inc., Waltham, MA, USA) on a Jupiter C~18~ analytical column (5 µm particle size, 300 Å pore size, 4.6×250 mm) (Phenomenex). Electron spray ionization LC/MS (electrospray ionization \[ESI\] LC/MS) was performed using a Thermo Electron MSQ Surveyor. Compounds were characterized by nuclear magnetic resonance (NMR) on a Varian^UNITY^ INOVA 600 spectrometer, equipped with a cold-probe and an INOVA 400 spectrometer provided with Z-axis pulsed-field gradients and a triple resonance probe.

Peptide synthesis
-----------------

The peptide was synthesized using the standard solid-phase 9-fluorenylmethoxycarbonyl (Fmoc) method as previously reported.[@b12-ijn-10-6523] The Wang resin (Sigma-Aldrich Co.) (substitution 1.0 mmol/g) was used as solid-phase support, and syntheses were performed on a scale of 100 µmol. The peptide was fully deprotected and cleaved from the resin with trifluoroacetic acid (TFA) with 5% thioanisole, 3% ethanedithiol, and 2% anisole as scavengers. The crude peptide was precipitated with ice-cold ethyl ether, filtered, dissolved in water, lyophilized, and reduced with dithiothreitol. It was purified to homogeneity by preparative reverse-phase high-pressure liquid chromatography (HPLC). The sample was injected on a Phenomenex C~18~ column (22 mm ×25 cm, 5 µm) eluted by: 1) H~2~O/0.1% TFA and 2) CH~3~CN/0.1% TFA solvent mixture. A linear gradient from 5% to 50% of CH~3~CN/0.1% TFA solvent mixture over 17 minutes at a flow rate of 20 mL/min was used. The collected fractions were lyophilized to dryness and analyzed by analytical reverse-phase HPLC using a Phenomenex C~18~ analytical column (4.6×250 mm, 5 mm). The identity of the purified peptide was confirmed by electron spray ionization LC/MS using a Thermo Electron MSQ Surveyor. The purified peptide was oxidized at a maximum concentration of 1 mg/mL in order to favor intramolecular interactions and avoid the formation of dimeric species; then, the oxidized peptide was further purified. Briefly, peptide oxidation was performed by dissolving 1 mg/mL of the crude peptide in a 0.1 M solution of ammonium bicarbonate at pH 8.2, leaving the mixture in contact with air for 24 hours. Reactions were monitored by LC/MS analysis. The oxidized AMC analog was purified by preparative reverse-phase HPLC (Shimadzu SPD-10A VP UV-Vis detector) using a gradient of acetonitrile (0.1% TFA) in water from 5% to 70% for 20 minutes and a Jupiter column (10 µm, Proteo 90 Å, 250×21 mm). The purity of the cyclic defensin analog AMC is over 99% as checked by LC/MS.

NMR
---

NMR spectra were acquired at 298 K on a Varian^UNITY^ INOVA 600 spectrometer, equipped with a cold-probe and an INOVA 400 spectrometer provided with Z-axis pulsed-field gradients and a triple resonance probe. NMR samples consisted of the AMC peptide (1 mg) dissolved in either 600 µL of H~2~O/deuterium oxide (D~2~O) (99.8% d; Armar Scientific, Döttingen, Switzerland) (90/10 v/v) or a mixture of H~2~O/2-2-2 trifluoroethanol-d3 (TFE) (98% d; Armar Chemicals, Döttingen, Switzerland) (20/80 v/v). Trimethylsilyl-3-propionic acid sodium salt-d4 (99% d; Armar Scientific) was used as internal standard for chemical shift referencing. Water suppression was achieved with the double pulsed field gradient selective echo sequence.[@b13-ijn-10-6523] 1D \[^1^H\] proton experiments were recorded with a relaxation delay of d1=1.5 seconds and 64--128 scans. The process of proton resonance assignments ([Tables S1](#SD2-ijn-10-6523){ref-type="supplementary-material"} and [S2](#SD3-ijn-10-6523){ref-type="supplementary-material"}) was achieved with a standard method[@b14-ijn-10-6523] based on combined analysis of 2D \[^1^H, ^1^H\] total correlation spectroscopy (TOCSY)[@b15-ijn-10-6523] (70 ms mixing time) and Nuclear Overhauser enhancement spectroscopy (NOESY)[@b16-ijn-10-6523] (200 and 300 ms mixing times) experiments. The 2D \[^1^H, ^1^H\] double-quantum-filter correlation spectroscopy[@b17-ijn-10-6523] spectrum also served to confirm proton side-chain assignments. The NMR data were processed with the VNMRJ software (Agilent Technologies, Santa Clara, CA, USA). Two-dimensional NMR spectra were analyzed with NEASY,[@b18-ijn-10-6523] as implemented in CARA (<http://www.nmr.ch/>). Temperature coefficients (Δδ/ΔT) ([Tables S3](#SD4-ijn-10-6523){ref-type="supplementary-material"} and [S4](#SD5-ijn-10-6523){ref-type="supplementary-material"}) were evaluated by 2D \[^1^H, ^1^H\] TOCSY experiments that were recorded for peptide samples at the following temperatures: 298, 301, 304, 307, and 310 K. The software CYANA (version 2.1)[@b19-ijn-10-6523] was used for structure calculations ([Tables S5](#SD6-ijn-10-6523){ref-type="supplementary-material"} and [S6](#SD7-ijn-10-6523){ref-type="supplementary-material"}); distance constraints were generated from 2D NOESY 300 spectra.

Cell culture and cytotoxicity studies: 3-\[4.5-dimethylthiazol-2-yl\]-2.5-diphenyltetrazolium bromide test
----------------------------------------------------------------------------------------------------------

Parental CaCo-2 human cells stored in liquid nitrogen were thawed by gentle agitation of their vials for 2 minutes in a water bath at 37°C. After thawing, the content of each vial was transferred to a 75 cm^2^ surface area tissue culture flask and diluted with 90% Dulbecco's Modified Eagle's Minimal Essential Medium (Sigma-Aldrich Co.) supplemented with 10% fetal bovine serum (Lonza, Basel, Switzerland) and 1% L-glutamine (Sigma-Aldrich Co.). Then the cells were incubated for 24 hours at 37°C in 5% CO~2~ to allow them to grow and form a monolayer in the flask. Cells grown to 80%--95% confluency were washed with phosphate-buffered saline (PBS), trypsinized with 3 mL of trypsin-EDTA solution (1X) (Sigma-Aldrich Co.), diluted, counted, and seeded (4×10^3^ cells/200 µL per well) into 96-well microtiter tissue culture plates for 24 hours in triplicate. The reduction in the proliferation of the cells was evaluated by the 3-\[4.5-dimethylthiazol-2-yl\]-2.5-diphenyltetrazolium bromide (MTT) (Sigma-Aldrich Co.) assay which enables the measurement of metabolic changes. On the next day, cells were incubated at 37°C with or without wild-type hBD1 and hBD3 and the AMC analog according to different schemes: a) 2.5, 12.5, and 25 µM for 4, 8, 12, 16, 20, 24, 48, 72, and 168 hours; and b) 125 µM for 8, 24, and 72 hours. Adherent cells were stained with MTT dye solution, ie, 20 µL of 1:10 diluted MTT stock solution (5 mg/mL) and incubated for 4 hours. After incubation, we verified the presence of the violet crystals that normally indicate metabolization of MTT. Then the medium was removed (180 µL) and 180 µL of dimethyl sulfoxide (Sigma-Aldrich Co.) was added to dissolve the MTT crystals. The eluted specific stain was measured with a spectrophotometer (550 nm). The proliferation index of the untreated cells was compared to that of the negative control (cell plus medium without peptides). The experiments were performed in duplicate. Ethical approval was not sought for the use of this type of human cell lines.

Antibacterial activity
----------------------

A colony-forming unit assay (CFU) of the antibacterial activity of hBDs against *Pseudomonas aeruginosa* ATCC (American Type Culture Collection, Manassas, VA, USA) 27853, *Enterococcus faecalis* ATCC 29212, and *Escherichia coli* ATCC 25922 was performed. The strains were grown in aerobic conditions in tryptic soy broth (Difco Laboratories, Detroit, MI, USA) at 37°C and incubated in the presence of hBDs for 2 hours at 37°C in PBS. We used two concentrations of peptides, ie, 2.5 µM and 12.5 µM. For salt-dependence assay, 0, 50, 100, and 200 mM NaCl was included in the incubation PBS buffer for 2 hours at 37°C under non-proliferating conditions (see also Scudiero et al[@b7-ijn-10-6523] and Scudiero et al[@b8-ijn-10-6523]). A CFU assay was used to measure the antibacterial activity of hBD1, hBD3, and the AMC analog against *E. coli*, *P. aeruginosa*, and *E. faecalis* also in the presence of various concentrations of Ca^2+^ and Mg^2+^ ions. The strains were incubated for 2 hours at 37°C with two peptide concentrations (2.5 and 12.5 µM) in the presence of Ca^2+^ and Mg^2+^ ions (0, 0.1, and 1 mM) in 150 mM TRIS buffer. Each assay was performed in triplicate. Bactericidal activity (mean and standard deviation of three assays) is expressed as the ratio between colonies counted and the number of colonies on a control plate.

The minimal inhibitory concentration of the new molecule AMC was determined with a modified version of the microbroth dilution assay of the National Committee for Clinical Laboratory Standards using a final inoculum of 10^5^ CFU/mL. The following peptide concentrations were used: 100.0, 50.0, 25.0, 12.5, 6.25, 3.12, and 1.56 µM.

The growth performance of *P. aeruginosa* ATCC 27853, *E. faecalis* ATCC 29212, and *E. coli* ATCC 25922 was also tested. Bacterial absorbance of the overnight culture was determined and adjusted to 0.2 at OD~600~. Bacteria were then incubated in the presence or absence of the AMC analog at 37°C (5% CO~2~). Duplicate absorbance readings (OD~600~) of bacterial cultures were taken every 30 minutes for 21 hours. Absorbance readings were plotted against time to generate bacterial growth curves.

Antiviral activity
------------------

Vero cells were grown in Dulbecco's Modified Eagle's Medium supplemented with 10% fetal calf serum. Herpes simplex virus (HSV)-1 carrying a lacZ gene driven by the cytomegalovirus IE-1 promoter to express beta-galactosidase was propagated as described elsewhere.[@b20-ijn-10-6523] All experiments were conducted in parallel with no-peptide controls. The effect of peptides on inhibition of HSV infectivity on cell monolayers[@b20-ijn-10-6523] was assessed as follows: For "co-exposure" experiments, the cells were incubated with increasing concentrations of the peptides (1, 5, 10.0, 20.0, 50.0, 100.0, and 150.0 µM) and with the viral inoculum for 45 minutes at 37°C. Non-penetrated viruses were inactivated by citrate buffer at pH 3.0. Monolayers were fixed, stained with 5-bromo-4-chloro-3-indolyl-beta-D-galactopyranoside and plaque numbers were scored. Experiments were performed in triplicate and the percentage of inhibition was calculated with respect to no-peptide control experiments.For "virus pre-exposure" experiments, approximately 2×10^4^ plaque-forming unit (PFU) of HSV-1 were incubated with 20 µM of peptides for 45 minutes at 37°C then titrated on Vero cell monolayers.For "cell pre-exposure" experiments, Vero cells were incubated with 20 µM of peptides for 30 minutes at 4°C and infected with serial dilutions of HSV-1 for 45 minutes at 37°C.

Serum stability
---------------

The serum stability of AMC peptides, in reduced and oxidized form, was assessed at 0, 0.5, 1, 2, 3, 6, 8, 24, and 72 hours as reported elsewhere.[@b8-ijn-10-6523] Supernatants were analyzed by LC/MS using a combined system constituted by a reverse-phase HPLC (Gilson, Middleton, USA) interfaced with a Flexar SQ 300 mass spectrometer with electrospray ionization (PerkinElmer Inc.). Components were separated using a reverse-phase Jupiter C~18~ analytical column (5 µm particle size, 300 Å pore size, 4.6×250 mm) (Phenomenex) with a linear gradient of 5%--60% acetonitrile in acidified water (0.1% TFA) over 30 minutes. Peptide cleavage in serum was assessed by electron spray ionization mass spectrometry analysis. Mass spectrometry was performed in the mass range from 200 to 3,000 m/z.

Results and discussion
======================

Design and synthesis of the new cyclic peptide
----------------------------------------------

A novel molecule, designated AMC, containing the internal hydrophobic domain of hBD1 and the C-terminal charged region of hBD3 was obtained from the cyclization of a 17 amino acid sequence ([Table 1](#t1-ijn-10-6523){ref-type="table"}). The internal domain was cyclized using two cysteine residues which were easily oxidized to obtain the molecule containing the charged hBD3 domain at its C-terminus. In this molecule, the cycle and the charged region are separated by two glycine residues (GG spacer) in order to allow sufficient flexibility of the two domains. The peptide was synthesized using the standard solid-phase-Fmoc method as previously reported,[@b10-ijn-10-6523] and the purified reduced peptide yield was higher (\>60%) than the yields usually obtained for defensin peptides. The purified peptide was oxidized to obtain the final molecule and further purified.

Characterization of the AMC structure
-------------------------------------

We first investigated the conformational properties of the AMC peptide in H~2~O/D~2~O (90/10 v/v) at pH =4.2. The Nuclear Overhauser effect (NOE) diagram ([Figure S1A](#SD1-ijn-10-6523){ref-type="supplementary-material"}) is not consistent with the presence of ordered secondary structure elements.[@b14-ijn-10-6523] The high absolute values of temperature coefficients (\|Δδ/ΔT\| higher than 4 ppb/K) ([Table S3](#SD4-ijn-10-6523){ref-type="supplementary-material"}) obtained for the majority of residues indicate that most amide protons are solvent-exposed and are unlikely to be involved in the formation of hydrogen bonds.[@b21-ijn-10-6523]

In the NOESY[@b16-ijn-10-6523] spectrum of the AMC peptide in H~2~O, we clearly identified the NOE contact between the Hα proton of Cys1 and the Hδδ' protons of Pro2, which is indicative of a proline in a trans configuration.[@b14-ijn-10-6523] In the TOCSY[@b15-ijn-10-6523] and NOESY[@b16-ijn-10-6523] spectra, besides the unambiguously assigned spin systems ([Table S1](#SD2-ijn-10-6523){ref-type="supplementary-material"}), there were sets of lower-intensity signals. This feature could result from proline cis--trans isomerization; however, because of spectral overlaps and closeness of the chemical shifts of the Hα protons to the water signal, we could not clearly distinguish NOE contacts characteristic of a proline in a cis configuration. For structural calculations, only the higher-intensity spin systems were considered and thus the proline was set in a trans configuration. The NMR solution structure was calculated with the torsion angle dynamics algorithm of the CYANA software[@b19-ijn-10-6523] ([Table S5](#SD6-ijn-10-6523){ref-type="supplementary-material"}). The NMR conformers appeared rather disordered, also in the cyclic portion Cys1--Cys11, as indicated by the high root mean square deviation (RMSD) values, and were subjected to a clusterization procedure ([Figure 1A--D](#f1-ijn-10-6523){ref-type="fig"}; [Table S7](#SD8-ijn-10-6523){ref-type="supplementary-material"}). Clusters were generated with the Chimera program[@b22-ijn-10-6523] by superimposing the final 20 NMR structures on the backbone atoms (residues 1--11). This analysis revealed three clusters that represent conformationally related subfamilies ([Figure 1A--D](#f1-ijn-10-6523){ref-type="fig"}); the most abundant cluster includes ten structures, and the other two clusters are populated each by five structures ([Table S7](#SD8-ijn-10-6523){ref-type="supplementary-material"}).

We also conducted NMR studies in a membrane mimetic environment (ie, in TFE/H~2~O 80/20 v/v) ([Table S2](#SD3-ijn-10-6523){ref-type="supplementary-material"}).[@b23-ijn-10-6523] The NOESY[@b16-ijn-10-6523] spectrum recorded in the presence of TFE contains more high-intensity contacts than in an H~2~O environment, thereby indicating a clear increase in ordered conformations. The NOE pattern (ie, a stretch of strong H~N~i−H~N~i+1; Hαi−H~N~i+2; Hαi−H~N~i+3; Hαi−Hβi+3 connectivities) indicates the presence of a helix in the peptide segment encompassing residues Ile3 and Gln8 ([Figure S1B](#SD1-ijn-10-6523){ref-type="supplementary-material"}).

A 3D model of AMC in the presence of TFE was constructed ([Figure 1E and F](#f1-ijn-10-6523){ref-type="fig"}; [Table S6](#SD7-ijn-10-6523){ref-type="supplementary-material"}). The peptide cyclic region encompassing the Cys1--Cys11 segment is well defined as indicated by the low RMSD values ([Table S6](#SD7-ijn-10-6523){ref-type="supplementary-material"}), and the region-spanning residues Phe4--Ile7 adopt a 3.10 helix conformation ([Figure 1E and F](#f1-ijn-10-6523){ref-type="fig"}). Indeed, low absolute values of temperature coefficients, below 4 ppb/K, which is indicative of scarce solvent exposure,[@b21-ijn-10-6523] were measured for residues in the helical region, namely Phe4, Thr5, and Lys6, as well as for Gly9 and Cys11 ([Table S4](#SD5-ijn-10-6523){ref-type="supplementary-material"}). In the NOESY spectrum, we unambiguously assigned the NOE contacts Hα Cys1--Hδδ' Pro2 that are diagnostic of a proline in a trans configuration.[@b14-ijn-10-6523] However, as discussed above for the peptide sample in H~2~O, we cannot exclude some cis--trans pro-isomerization also in the presence of TFE.

In summary, when analyzed by NMR in H~2~O, the structure of the AMC peptide was found to be rather disordered in both the cyclic and C-terminal regions ([Figure 1](#f1-ijn-10-6523){ref-type="fig"}). A strict comparison between the conformation assumed by AMC and those of the corresponding regions of hBD1 and hBD3 is not feasible due to the high flexibility of the peptide in aqueous solution. However, as can be clearly seen in [Figure 2](#f2-ijn-10-6523){ref-type="fig"}, where a representative AMC structure is taken into account, the insertion of the disulfide bridge between the two cysteines likely constrains the AMC peptide backbone which thereby assumes a structure that resembles the corresponding region of hBD1. NMR analysis in a membrane mimetic environment like TFE revealed an increase of order in the AMC cyclic region, which gained a small helical turn encompassing residues Phe4--Ile7 ([Figure 1](#f1-ijn-10-6523){ref-type="fig"}). It cannot be excluded that a structural rearrangement may occur in the peptide once it interacts with membranes, and in this respect, the structure observed in TFE may represent a bioactive AMC conformation.

Cytotoxicity of wild-type hBD1 and hBD3 and analog AMC in CaCo-2 cells
----------------------------------------------------------------------

The MTT test was performed on CaCo-2 cells using wild-type hBD1 and hBD3, and their analog AMC at concentrations of 2.5, 12.5, and 25.0 µM. Exposure times were 4, 8, 12, 16, 20, 24, 48, and 72 hours. Since similar results were obtained with the three concentrations, we report only the results obtained with the highest concentration. [Figure 3A](#f3-ijn-10-6523){ref-type="fig"} shows the percentage of viability of CaCo-2 cells exposed to the peptides at a concentration of 25.0 µM. These results confirm our previous results obtained with hBD1 and hBD3.[@b7-ijn-10-6523] At all peptide concentrations used, cell viability was only slightly reduced after 24 hours (5%--20%), whereas it was reduced by approximately 25% after 48 and 72 hours ([Figure 3A](#f3-ijn-10-6523){ref-type="fig"}). Moreover, we performed toxicity assays at a peptide concentration of 125 µM for 8, 24, and 72 hours of incubation ([Figure 3B](#f3-ijn-10-6523){ref-type="fig"}). In these conditions, we found a more pronounced reduction in cell viability; for all tested peptides, cell viability was reduced by 40% after 8 hours and by approximately 50% after 24 and 72 hours. In conclusion, this set of experiments shows that the wild-type hBDs and AMC do not induce relevant cytotoxic effects in vitro at concentrations of 2.5, 12.5, and 25.0 µM.

Antibacterial activity of the AMC analog compared to the parent hBDs
--------------------------------------------------------------------

We analyzed the antibacterial activity of the AMC analog and of hBD1 and hBD3 as reference peptides.[@b7-ijn-10-6523],[@b8-ijn-10-6523] We tested two concentrations of each peptide (2.5 and 12.5 µM) and four concentrations of NaCl (0, 50, 100, and 200 mM) against *P. aeruginosa, E. coli*, and *E. faecalis*, which are the most frequent causes of many human infections. Firstly, we tested the antibacterial properties of AMC in the reduced and oxidized forms against *E. coli*. The reduced form of AMC was less active than the oxidized form (data not shown). This behavior may be due to the structural features of AMC and its flexibility. Therefore, we decided to test only the oxidized form for the other bacterial strains (*P. aeruginosa* and *E. faecalis*). The results confirmed the antibacterial properties of hBD1 and the salt resistance of hBD3.[@b7-ijn-10-6523],[@b8-ijn-10-6523] Tested against *P. aeruginosa* at 2.5 µM, AMC exerted similar antibacterial activity to hBD3 in the presence of 200 mM NaCl; at a concentration of 12.5 µM, AMC was more active at 200 mM NaCl ([Figure 4A](#f4-ijn-10-6523){ref-type="fig"}). Interestingly, the antibacterial activity of AMC against *E. coli* and *E. faecalis* was similar to that of hBD3 in the presence of up to 100 mM salt at both 2.5 and 12.5 µM of peptide. AMC exerted the best antibacterial activity at 12.5 µM; at this concentration it was more effective than hBD3 in the presence of the highest salt concentration (200 mM) ([Figure 4B and C](#f4-ijn-10-6523){ref-type="fig"}).

Since divalent cations (magnesium and calcium) decrease the antimicrobial activity of peptides, we performed a CFU assay in the presence of Ca^2+^ and Mg^2+^ (0.1 and 1 mM, respectively) against *P. aeruginosa, E. coli*, and *E. faecalis*. The results are shown in [Figure 5](#f5-ijn-10-6523){ref-type="fig"}. Against *P. aeruginosa* and *E. coli*, hBD1, hBD3, and AMC lose their activity to a similar extent in the presence of Ca^2+^ and Mg^2+^ ([Figure 5A and B](#f5-ijn-10-6523){ref-type="fig"}). Interestingly, the antibacterial activity of hBD1, hBD3, and AMC against *E. faecalis* in the presence of Ca^2+^ and Mg^2+^ was retained compared with the samples without these ions indicating that the influence of cations strictly depends on the bacteria strains ([Figure 5C](#f5-ijn-10-6523){ref-type="fig"}). Moreover, we evaluated AMC minimal inhibitory concentration, which ranged between 12.5 and 25.0 µM in the tested microorganisms.

Finally, we tested the effect exerted by AMC on the growth performance of the indicator strains, and found that it prolonged the lag phase and reduced the maximum population level after 48 hours of incubation ([Figure 6](#f6-ijn-10-6523){ref-type="fig"}). These antibacterial tests provide an indication about the effects of the new synthetized AMC; in fact, we observed a delay in the lag phase of the three bacteria tested in the presence of 2.5 µM, with a longer lag phase of 7.5 hours versus 4 hours.

AMC exerts good antiviral activity against HSV type 1
-----------------------------------------------------

We evaluated the antiviral activity of AMC, both oxidized and reduced, and compared it to the activity of hBD3. All peptides inhibited HSV infectivity in a dose-dependent manner ([Figure 7](#f7-ijn-10-6523){ref-type="fig"}). We evaluated the antiviral activities in co-exposure experiments ([Figure 7A](#f7-ijn-10-6523){ref-type="fig"}) (with cell, virus, and peptide at zero time), in virus pre-exposure experiments ([Figure 7B](#f7-ijn-10-6523){ref-type="fig"}) (virus plus peptide before cell infection), in cell pre-exposure experiments ([Figure 7C](#f7-ijn-10-6523){ref-type="fig"}) (cell plus peptide before virus infection), and in post-treatment (cell plus virus before peptide addition). This allowed us to evaluate if and in which phase the peptides inhibited virus infectivity. The reduced form of AMC was always less active than the oxidized form. Notably, we previously reported that oxidized and reduced hBD3 had the same antiviral activity.[@b7-ijn-10-6523] This discrepancy may reflect the small size of AMC and its flexibility. The disulfide bridge may be necessary to make the molecule more rigid and assume the correct folding for interaction. Both in the co-exposure and virus pre-treatment experiments, the oxidized AMC reduced virus infectivity by 60% at 150 µM, while infectivity was reduced by 30% in the cell-pre-treatment experiment, and no effect was found in the post-treatment experiment. These results suggest that AMC can interfere with viral attachment and entry; however, we found no proof of inhibition when cells were already infected. The oxidized AMC has a half maximal inhibitory concentration of 100 µM and hBD3 has a half maximal inhibitory concentration of 10 µM. This difference is probably due to the small size of AMC (17 residues versus 45 residues of hBD3), and AMC may thus represent a good starting point for next-generation analogs.

Human serum stability
---------------------

To evaluate the stability of oxidized AMC to the proteolytic effect of serum, peptide aliquots were incubated with 20% (v/v) human serum for different times and then analyzed by liquid chromatograph/mass spectrometry for peptide integrity ([Table 2](#t2-ijn-10-6523){ref-type="table"}; [Figure 8A--F](#f8-ijn-10-6523){ref-type="fig"}). The reduced AMC peptide was quickly degraded after 0.5 hours of incubation (data not shown). On the contrary, the integral oxidized peptide was detected, mixed with its degradation product, after 0.5 hours of incubation. Peptide degradation started at the C-terminus, --K after 0.5 hours of incubation and --KKR after 2 hours of incubation, as detected by mass spectrometric analysis ([Table 2](#t2-ijn-10-6523){ref-type="table"}; [Figure 8B and C](#f8-ijn-10-6523){ref-type="fig"}). The integral peptide disappeared after 2 hours of incubation ([Table 2](#t2-ijn-10-6523){ref-type="table"}; [Figure 8C](#f8-ijn-10-6523){ref-type="fig"}) and peptide degradation continued at the C-terminus --GRRKK up to 24 hours ([Table 2](#t2-ijn-10-6523){ref-type="table"}; [Figure 8F](#f8-ijn-10-6523){ref-type="fig"}), which suggests that degradation is mediated by a carboxypeptidase. At 72 hours, peptide degradation did not seem to proceed further, suggesting that serum peptide sensitivity is reduced by the presence of the disulfide bridge (data not shown).

Discussion
==========

The development of peptidomimetics which mimic the active conformation of a peptide by incorporating non-peptidic features has recently received much attention, resulting in many cases in improved pharmacological properties. Introduction of structural restraints is frequently used by the pharmaceutical industry to reduce the number of conformations and may result in higher affinity for the target and improved protease stability, bioavailability, and specificity. In fact, cyclization though disulfide bonds is naturally found in AMPs, such as the hBDs, which display highly potent and broad antimicrobial activity. The highly conserved triple-disulfide scaffold characteristic of hBDs makes their accessibility through chemical synthesis difficult and poor-yielding. In addition to the high cost, this complexity limits the number of analogs that can be produced to identify better therapeutic candidates.

In an effort to preserve the antimicrobial properties of hBDs while simplifying the structure of the molecule, we took advantage of our previous study of chimerae between the hBDs 1--3. Having established that the key domains involved in the antibacterial and antiviral activities were the RRKK of hBD3 and PIFTKIQGT, we combined them in a single-disulfide peptide, AMC. Analog AMC is an effective, highly stable, low-toxic, cyclic mini-β-defensin AMP. It recapitulates the antibacterial and antiviral properties of hBDs in a considerably smaller sequence (only 17 amino acids). Moreover, its ease of synthesis will enable the ready preparation of analogs to further improve biological potency and in vivo duration of action. Therefore, this molecule should be considered a new weapon with which to combat infectious diseases. Additional values that may be considered are its potential use in case of antibiotic resistance and its delivery by way of nanovector devices.
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###### 

Summary of main short and medium range NOEs.

**Notes:** NOE pattern of AMC in (**A**) H~2~O/D~2~O (90/10) and (**B**) TFE/H~2~O (80/20). A NOE correlation between protons a and b in the i and i+*x* amino acid is indicated by dabi, *i*+*x*; for example d~NN~(*i*,*i*+1) represents a NOE contact in between backbone amide protons in sequential amino acid residues (ie, numbers *i* and *i*+1 respectively); similarly *d*~αβ~(*i*,*i*+3) represents a correlation between the H~α~ proton of residue number *i* and the H~β~ proton of residue number *i*+3. The thickness of the bars reflects NOE intensity. The amino acid sequence of AMC is shown in a single letter code. The graph was generated with CYANA.[@b24-ijn-10-6523]

**Abbreviations:** AMC, antimicrobial cyclic peptide; D~2~O, deuterium oxide; NOE, Nuclear Overhauser effect; TFE, 2-2-2 trifluoroethanol-d3.

###### 

Chemical shifts (ppm) of the AMC peptide in H~2~O/D~2~O (90/10)

  Residue   H~N~   Hα     Hβ     Hγ           Others
  --------- ------ ------ ------ ------------ ---------------
  1 C              4.66   3.36                
                          3.17                
  2 P              4.51   2.28   2.00         Hδ 3.80, 3.61
                          1.72                
  3 I       8.20   3.98   1.77   1.40, 1.12   Hδ 0.83
                                 γCH3 0.81    
  4 F       8.04   4.70   3.16                Hδ 7.26
                          3.13                Hε 7.35
  5 T       7.78   4.30   4.20   1.12         
  6 K       8.17   4.22   1.82   1.47         Hδ 1.66
                                 1.36         Hε 2.97
  7 I       7.95   4.14   1.83   1.46, 1.15   Hδ 0.85
                                 γCH3 0.88    
  8 Q       8.47   4.19   2.12   2.36         Hε 7.49, 6.86
                          2.02                
  9 G       8.29   4.03                       
                   3.94                       
  10 T      8.04   4.44   4.25   1.17         
  11 C      8.63   4.69   3.28                
                          3.14                
  12 G      8.62   4.01                       
                   3.98                       
  13 G      8.23   4.00                       
                   3.99                       
  14 R      8.25   4.34   1.82   1.63         Hδ 3.21
                          1.74                Hε 7.20
  15 R      8.44   4.33   1.83   1.63         Hδ 3.20
                          1.77                Hε 7.21
  16 K      8.42   4.30   1.82   1.43         Hδ 1.70
                                              Hε 3.00
  17 K      7.99   4.11   1.75   1.39         Hδ 1.70
                                              Hε 2.99

**Abbreviations:** AMC, antimicrobial cyclic peptide; D~2~O, deuterium oxide; ppm, parts per million; C, cysteine; P, proline; I, isoleucine; F, phenylalanine; T, threonine; K, lysine; Q, glutamine; G, glycine; R, arginine.

###### 

Chemical shifts (ppm) of the AMC peptide in TFE/H~2~O (80/20)

  Residue   H~N~   Hα     Hβ     Hγ           Others
  --------- ------ ------ ------ ------------ ---------------
  1 C              4.51   3.41                
                          3.33                
  2 P              4.56   2.31   2.06         Hδ 3.77, 3.65
                          1.52   2.02         
  3 I       8.24   3.92   1.90   1.49, 1.23   Hδ 0.94
                                 γCH3 0.88    
  4 F       7.00   4.54   3.21                Hδ 7.21
                          3.16                Hε 7.39
                                              Hζ 7.34
  5 T       7.30   4.36   4.30   1.14         
  6 K       7.66   4.31   1.96   1.55         Hδ 1.72
                                 1.42         Hε 3.02
  7 I       7.76   4.00   1.96   1.64, 1.25   Hδ 0.94
                                 γCH3 0.99    
  8 Q       7.99   4.24   2.26   2.54         Hε 7.00, 6.34
                          2.13   2.45         
  9 G       7.91   4.25                       
                   3.92                       
  10 T      8.02   4.46   4.42   1.21         
  11 C      7.97   4.64   3.24                
                          3.14                
  12 G      8.40   4.07                       
                   3.91                       
  13 G      8.03   4.03                       
                   3.95                       
  14 R      7.93   4.38   1.93   1.71         Hδ 3.22
                          1.83                
  15 R      7.98   4.37   1.94   1.69         Hδ 3.22
                          1.83                
  16 K      7.82   4.38   1.92   1.49         Hδ 1.74
                          1.81                Hε 3.04
  17 K      7.93   4.38   1.92   1.50         Hδ 1.74
                                              Hε 3.03

**Abbreviations:** AMC, antimicrobial cyclic peptide; TFE, 2-2-2 trifluoroethanol-d3; ppm, parts per million; C, cysteine; P, proline; I, isoleucine; F, phenylalanine; T, threonine; K, lysine; Q, glutamine; G, glycine; R, arginine.

###### 

Temperature coefficients of the AMC peptide in H~2~O/D~2~O (90/10)

  Residue   Δδ/ΔT (ppb/K)
  --------- ---------------
  1 C       --
  2 P       --
  3 I       −9.0±0.3
  4 F       −7.5±0.3
  5 T       −4.1±0.3
  6 K       −5.5±0.4
  7 I       −6.4±0.3
  8 Q       −8.4±0.2
  9 G       −5.9±0.7
  10 T      −4.9±0.5
  11 C      −7.7±0.3
  12 G      −7.83±0.07
  13 G      −5.67±0.23
  14 R      −6.4±0.2
  15 R      −7.9±0.8
  16 K      −7.5±0.4
  17 K      −7.9±0.2

**Notes:** Data are presented as mean ± standard deviation.

**Abbreviations:** AMC, antimicrobial cyclic peptide; D~2~O, deuterium oxide; C, cysteine; P, proline; I, isoleucine; F, phenylalanine; T, threonine; K, lysine; Q, glutamine; G, glycine; R, arginine.

###### 

Temperature coefficients of the AMC peptide in TFE/H~2~O (80/20)

  Residue   Δδ/ΔT (ppb/K)
  --------- ---------------
  1 C       --
  2 P       --
  3 I       −10.0±0.4
  4 F       −1.5±0.3
  5 T       −0.6±0.3
  6 K       −1.1±0.5
  7 I       −4.7±0.7
  8 Q       −5.8±0.6
  9 G       −3.3±0.8
  10 T      −5.0±0.5
  11 C      −2.6±0.5
  12 G      −6.5±0.3
  13 G      −5.3±0.4
  14 R      --
  15 R      −4.5±0.8
  16 K      −6.7±0.6
  17 K      −5.6±0.6

**Notes:** Δδ/ΔT for Arg14 could not be determined due to chemical shift overlaps at higher temperatures. Data are presented as mean ± standard deviation.

**Abbreviations:** AMC, antimicrobial cyclic peptide; TFE, 2-2-2 trifluoroethanol-d3; C, cysteine; P, proline; I, isoleucine; F, phenylalanine; T, threonine; K, lysine; Q, glutamine; G, glycine; R, arginine.

###### 

Structure statistics for the AMC NMR conformers in H~2~O/D~2~O (90/10)

  ---------------------------------------------------------------------- -----------
  NOE upper distance limits                                              125
  Angle constraints                                                      71
  Residual target function, Å[@b25-ijn-10-6523]                          0.17±0.02
  Residual NOE violations                                                
  Total Number \>0.1 Å[\*](#tfn10-ijn-10-6523){ref-type="table-fn"}      1
  Maximum Å                                                              0.24
  Residual angle violations                                              
  Total number                                                           0
  Atomic pairwise RMSD,[\#](#tfn11-ijn-10-6523){ref-type="table-fn"} Å   
  Backbone atoms (a.a. 1--11)                                            0.92±0.30
  Heavy atoms (a.a. 1--11)                                               1.52±0.45
  Ramachandran statistics[‡](#tfn12-ijn-10-6523){ref-type="table-fn"}    
  Residues in core regions                                               40.6%
  Residues in allowed regions                                            57.5%
  Residues in generous regions                                           1.9%
  Residues in disallowed regions                                         0.0%
  ---------------------------------------------------------------------- -----------

**Notes:**

Average CYANA[@b24-ijn-10-6523] violations;

evaluated with iCing;[@b25-ijn-10-6523]

Procheck-NMR[@b28-ijn-10-6523] analysis (residues 1--11). Structures were generated from 125 NOE upper distance limits (52 intra-residue, 62 sequential, 8 medium-range, and 3 long-range); three upper and three lower distance limits were enforced for the disulfide bridge. Structure calculations initiated from 100 random conformers; in the end, the 20 structures with the lowest CYANA[@b24-ijn-10-6523] target functions and showing largest agreement with the experimental restraints were considered representative and, thus, incorporated in the NMR ensemble. These structures were additionally analyzed with the molecular graphic programs MOLMOL[@b27-ijn-10-6523] and UCSF Chimera[@b28-ijn-10-6523] and validated with iCing.[@b25-ijn-10-6523] Data are presented as mean ± standard deviation.

**Abbreviations:** a.a., amino acid; AMC, antimicrobial cyclic peptide; D~2~O, deuterium oxide; NMR, nuclear magnetic resonance; NOE, Nuclear Overhauser effect; RMSD, root mean square deviation; CYANA, Combined Assignment and Dynamics Algorithm for NMR Applications; UCSF, University of California San Francisco.

###### 

Structure statistics for AMC NMR ensemble of structures in TFE/H~2~O (80/20)

  ---------------------------------------------------------------------- -----------
  NOE upper distance limits                                              175
  Angle constraints                                                      74
  Residual target function, Å[@b25-ijn-10-6523]                          0.21±0.02
  Residual NOE violations                                                
  Total Number \>0.1 Å[\*](#tfn14-ijn-10-6523){ref-type="table-fn"}      1
  Maximum Å                                                              0.23
  Residual angle violations                                              
  Total number                                                           0
  Atomic pairwise RMSD,[\#](#tfn15-ijn-10-6523){ref-type="table-fn"} Å   
  Backbone atoms (a.a. 1--11)                                            0.22±0.17
  Heavy atoms (a.a. 1--11)                                               0.65±0.15
  Ramachandran statistics[‡](#tfn16-ijn-10-6523){ref-type="table-fn"}    
  Residues in core regions                                               68.8%
  Residues in allowed regions                                            25.0%
  Residues in generous regions                                           6.3%
  Residues in disallowed regions                                         0.0%
  ---------------------------------------------------------------------- -----------

**Notes:**

Average CYANA[@b24-ijn-10-6523] violations;

evaluated with iCing;[@b27-ijn-10-6523]

Procheck-NMR[@b28-ijn-10-6523] analysis (residues 1--11). The final structure calculation included 175 upper limit distance restraints from NOE data (83 intra-residue, 58 short-range, 22 medium-range, and 12 long-range) together with three lower limit distance constraints that were inserted for the disulfide bridge between Cys1 and Cys11. Calculations started from 100 random conformers; the 20 structures with the lowest CYANA target functions were included in the NMR ensemble and additionally inspected with the programs MOLMOL,[@b25-ijn-10-6523] UCSF Chimera,[@b26-ijn-10-6523] and iCing.[@b27-ijn-10-6523] Data are presented as mean ± standard deviation.

**Abbreviations:** a.a., amino acid; AMC, antimicrobial cyclic peptide; NMR, nuclear magnetic resonance; NOE, Nuclear Overhauser effect; RMSD, root mean square deviation; TFE, 2-2-2 trifluoroethanol-d3; CYANA, Combined Assignment and Dynamics Algorithm for NMR Applications; UCSF, University of California San Francisco.

###### 

Cluster analysis of the AMC NMR ensemble calculated in H~2~O/D~2~O

  Cluster   Model numbers[\*](#tfn18-ijn-10-6523){ref-type="table-fn"}   Representative structure[\#](#tfn19-ijn-10-6523){ref-type="table-fn"}
  --------- ------------------------------------------------------------ -----------------------------------------------------------------------
  1         2-4-5-6-7-10-11-12-13-14                                     2
  2         9-15-16-17-18                                                17
  3         1-3-8-19-20                                                  8

**Notes:**

Numbers refer to CYANA[@b24-ijn-10-6523] structures; lower numbers indicate better models in terms of experimental constraints violations.

Representative models were chosen by the software Chimera[@b26-ijn-10-6523] using the approach described in Kelley et al.[@b29-ijn-10-6523]

**Abbreviations:** AMC, antimicrobial cyclic peptide; D~2~O, deuterium oxide; NMR, nuclear magnetic resonance.
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![Solution structure of AMC in H~2~O/D~2~O (90/10) (**A**--**D**) and in TFE/H~2~O (80/20) (**E**, **F**).\
**Notes:** (**A**) Twenty NMR structures are overlaid on the backbone atoms of residues 1--11. (**B**--**D**) Representative models from different structural clusters. The disulfide bridge between Cys1 and Cys11 is shown. (**E**) Superposition on the backbone atoms (residues 1--11) of 20 NMR conformers. (**F**) Ribbon representation of the NMR conformer number 1, which possesses the lowest CYANA[@b19-ijn-10-6523] target function and better fits the experimental restraints. The side chains of Cys1 and Cys11 are shown together with the disulfide bridge.\
**Abbreviations:** AMC, antimicrobial cyclic peptide; NMR, nuclear magnetic resonance; TFE, 2-2-2 trifluoroethanol-d3; N-ter, N-terminus; C-ter, C-terminus; Cys1, cysteine 1; Cys11, cysteine 11.](ijn-10-6523Fig1){#f1-ijn-10-6523}

![hBD1 (pdb code 1KJ5), AMC, and hBD3 (pdb code1KJ6) solution structures are shown on the left, in the middle, and on the right, respectively.\
**Notes:** Conformers number 1 of each NMR ensemble are shown in a ribbon representation. The backbone regions encompassing the CPIFTKIQGTC sequence are colored red on the AMC (middle) and hBD1 (left) structures, whereas the sequence RRKK is colored yellow (middle and right).\
**Abbreviations:** AMC, antimicrobial cyclic peptide; NMR, nuclear magnetic resonance; RRKK, charged C-terminal domain; N-ter, N-terminus; C-ter, C-terminus; Cys1, cysteine 1; Cys11, cysteine 11; Pdb, Protein Data Bank.](ijn-10-6523Fig2){#f2-ijn-10-6523}

![Cytotoxicity of wild-type hBD1, hBD3 and AMC.\
**Notes:** (**A**) Effect of 25 µM hBD1, hBD3, and AMC on the proliferation of CaCo-2 cells at 4, 8, 12, 16, 20, 24, 48, and 72 hours of incubation. (**B**) Effect of 125 µM hBD1, hBD3, and AMC at 8, 24, and 72 hours of incubation. The data are expressed as the percentage of absorbance at 550 nm relative to the control. The data are expressed as the mean ± standard deviation of one experiment performed in triplicate.\
**Abbreviation:** AMC, antimicrobial cyclic peptide.](ijn-10-6523Fig3){#f3-ijn-10-6523}

![Antibacterial activity of wild-type hBD1, hBD3 and AMC also in the presence of NaCl.\
**Notes:** The antibacterial activity of hBD1, hBD3, and AMC were tested at two concentrations (2.5 and 12.5 µM) against (**A**) *Pseudomonas aeruginosa*, (**B**) *Escherichia coli*, and (**C**) *Enterococcus faecalis* with 0, 50, 100, and 200 mM NaCl. Error bars show the standard deviations from three independent experiments.\
**Abbreviations:** AMC, antimicrobial cyclic peptide; CFU, colony-forming units.](ijn-10-6523Fig4){#f4-ijn-10-6523}

![Antibacterial activity of wild-type hBD1, hBD3 and AMC also in presence of Ca^2+^ and Mg^2+^.\
**Notes:** The antibacterial activity of hBD1, hBD3, and AMC was tested at two peptide concentrations (2.5 and 12.5 µM) against (**A**) *Pseudomonas aeruginosa*, (**B**) *Escherichia coli*, and (**C**) *Enterococcus faecalis* and with 0, 0.1, or 1 mM of Ca^2+^ or Mg^2+^. Error bars show the standard deviations from two independent experiments.\
**Abbreviations:** AMC, antimicrobial cyclic peptide; CFU, colony-forming units.](ijn-10-6523Fig5){#f5-ijn-10-6523}

![Growth curves of *Pseudomonas aeruginosa*, *Escherichia coli*, and *Enterococcus faecalis* incubated with 2.5 µM AMC (gray bar) and in Ctr (black bar).\
**Notes:** Representative results obtained for *P. aeruginosa.* Bacterial growth was followed from the beginning of growth until OD~600~ reached 1.2 after 21 hours of incubation. Error bars show the standard deviations from two independent experiments.\
**Abbreviations:** AMC, antimicrobial cyclic peptide; Ctr, control condition; OD, optical density.](ijn-10-6523Fig6){#f6-ijn-10-6523}

![Antiviral activity of AMC against Herpes simplex virus type 1.\
**Notes:** Reduced and oxidized AMC is compared to hBD3 in various experimental conditions: (**A**) co-exposure experiment; (**B**) virus pre-exposure experiment; and (**C**) cell pre-exposure experiment. Error bars show the standard deviation of experiments performed in triplicate.\
**Abbreviations:** AMC, antimicrobial cyclic peptide; ox, oxidized; red, reduced.](ijn-10-6523Fig7){#f7-ijn-10-6523}

###### 

Time-course of the incubation of oxidized AMC in human serum.

**Notes:** Upper panels of (**A**--**F**) show the HPLC analysis assessed at 0, 0.5, 2, 3, 6, and 24 hours of incubation, respectively; lower panels of (**A**--**F**) are respective mass spectra at the corresponding retention time.

**Abbreviations:** AMC, antimicrobial cyclic peptide; HPLC, high-performance liquid chromatography; TIC, total ion current.

![](ijn-10-6523Fig8)

![](ijn-10-6523Fig8a)

###### 

Sequences of the hBD1, AMC, and hBD3 peptides

  Peptide   Sequence   Charge
  --------- ---------- --------
  hBD1                 +4
  AMC                  +5
  hBD3                 +11

**Notes:** The sequence in the novel mini peptide is indicated according to the colors of hBD1 (red) and hBD3 (green); the broken line is merely spacing to highlight, at the level of this table, the homology between the AMC analog and natural defensins. Homology correspondence is indicated by color coding, and the red and green colors indicate the sequences taken from the defensins to construct the AMC mini-peptide. GG is a spacer that has been introduced to allow flexibility between the two domains, and it is of a different color: it is irrelevant where on the vertical axis they are put.

**Abbreviation:** AMC, antimicrobial cyclic peptide.

###### 

Time-course of the incubation of oxidized AMC in human serum

  Time (h)   Peptide sequence post-incubation   Theoretical Peptide Mass   Experimental Peptide Mass (m/z)   Charge
  ---------- ---------------------------------- -------------------------- --------------------------------- --------
  0          CPIFTKIQGTCGGRRKK                  1,891.32                   1,892.20                          +1
                                                                           946.42                            +2
                                                                           631.41                            +3
  0.5        CPIFTKIQGTCGGRRKK                  1,891.32                   1,892.20                          +1
                                                                           946.40                            +2
                                                                           631.42                            +3
             CPIFTKIQGTCGGRRK                   1,763.15                   1,764.32                          +1
                                                                           882.52                            +2
                                                                           588.77                            +3
  2          CPIFTKIQGTCGGRRK                   1,763.15                   1,764.35                          +1
                                                                           882.61                            +2
                                                                           588.66                            +3
             CPIFTKIQGTCGGRR                    1,634.98                   1,635.80                          +1
                                                                           818.361                           +2
                                                                           546.12                            +3
             CPIFTKIQGTCGGR                     1,478.79                   1,479.71                          +1
                                                                           740.462                           +2
                                                                           494.10                            +3
  3          CPIFTKIQGTCGGRR                    1,634.98                   1,635.95                          +1
                                                                           818.10                            +2
                                                                           545.93                            +3
             CPIFTKIQGTCGGR                     1,478.79                   1,479.67                          +1
                                                                           739.93                            +2
                                                                           494.06                            +3
  6          CPIFTKIQGTCGGR                     1,478.79                   1,479.40                          +1
                                                                           740.11                            +2
                                                                           494.10                            +3
  24         CPIFTKIQGTCGGR                     1,478.79                   1,479.70                          +1
                                                                           740.46                            +2
                                                                           494.11                            +3
             CPIFTKIQGTCGG                      1,322.60                   1,323.57                          +1
                                                                           662.22                            +2
                                                                           441.60                            +3
             CPIFTKIQGTCG                       1,265.55                   1,266.41                          +1
                                                                           633.24                            +2
                                                                           494.10                            +3

**Abbreviations:** AMC, antimicrobial cyclic peptide; h, hour.
